33A-1120517
US Provisional Application
We used flow cytometry to isolate memory B cells from COVID-19 convalescent people and applied human single B cell RT-PCR technology to generate human monoclonal antibodies (hAbs) against receptor binding domain (RBD) of SARS-CoV-2 spike protein. We identified that sixteen hAbs showed strongly neutralizing potency against SARS-CoV-2 BA.5. Among them, four hAbs exhibited strong binding and broad neutralizing performance against SARS-CoV-2 variants, including Alpha, Beta, Gamma, Delta, Omicron BA.5, BQ.1.1 and XBB.1.5 in pseudovirus assays. These data suggest that four human antibodies have the potential to the development of therapeutic drugs for the current COVID-19 epidemic caused by emerging variants.
1. Human antibodies have high specificity, low immune rejection and few side effects.
2. Anti-RBD hAbs have high neutralization activity and can be used to develop therapeutic antibodies.
3. High neutralization ability to the dominant strain of SARS-CoV-2, Omicron variants and Omicron subvariants, that are currently pandemic in the world.
Development of potently and broadly therapeutic antibody drugs for SARS-CoV-2 variants.
Han-Chung Wu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

The potently and broadly neutralizing human antibodies against SARS-CoV-2 from Alpha to Omicron